Quanterix Launches Novel P-Tau 205 and P-Tau 212 Assays to Advance Alzheimer's Research
核心洞察
Quanterix Corporation (搜索) has launched the first-to-market commercial p-Tau 205 (搜索) and p-Tau 212 (搜索) assays, expanding its blood-based biomarker portfolio for Alzheimer's disease (搜索) and neurodegeneration (搜索) research.
The new assays enable precise detection of tau phosphorylation sites associated with early and progressive stages of Alzheimer's disease (搜索), developed on the company's ultra-sensitive Simoa® platform.
Quanterix's recent acquisition of Akoya Biosciences (搜索) adds advanced spatial proteomics capabilities, creating a multi-dimensional approach that bridges soluble protein dynamics with spatial tissue context.
Quanterix Corporation (搜索) has announced the commercial launch of two novel phospho-tau assays, p-Tau 205 (搜索) and p-Tau 212 (搜索), marking the first-to-market availability of these biomarkers for Alzheimer's disease (搜索) research. The announcement coincides with the company's prominent presence at the Alzheimer's Association International Conference (AAIC) 2025, where more than 55 posters and presentations featured data generated using its Simoa® technology.
Expanding Biomarker Detection Capabilities
The newly launched assays enable precise detection of tau phosphorylation sites, biomarkers increasingly associated with early and progressive stages of Alzheimer's disease (搜索). Developed on Quanterix's ultra-sensitive Simoa® platform, the p-Tau 205 (搜索) and 212 assays are designed to empower researchers to explore novel disease mechanisms, refine patient stratification, and support therapeutic development through fluid-based biomarkers.
These additions strengthen Quanterix's market-leading portfolio of blood-based biomarkers for neurodegeneration (搜索) research. The company's Simoa® technology has previously demonstrated significant impact in Alzheimer's research, including powering breakthrough findings that detected rapid reduction of plasma P-tau217 (搜索) from donanemab, Eli Lilly's investigational antibody therapy, at 12 weeks in the Phase 2 TRAILBLAZER-ALZ study.
Strategic Integration with Spatial Biology
Quanterix's growing leadership in neurobiology was further reinforced by its recent acquisition of Akoya Biosciences (搜索), bringing advanced spatial proteomics into its scientific ecosystem. The Human FFPE Neurobiology Panel, originally developed by Akoya, complements the Simoa® platform by enabling high-plex, spatially resolved analysis of disease-specific protein expression in brain tissue.
"The addition of p-Tau 205 (搜索) and 212 strengthens our ability to support the scientific community in its pursuit of earlier detection, deeper understanding, and more personalized treatment approaches for Alzheimer's," said Masoud Toloue, PhD, CEO of Quanterix. "Combined with the recent integration of Akoya's spatial biology platform, we are now uniquely positioned to offer researchers a multi-dimensional view of pathobiology—bridging the gap between soluble protein dynamics and spatial tissue context."
Clinical and Research Applications
The newly launched p-Tau 205 (搜索) and p-Tau 212 (搜索) assays are now available to customers for use on the HD-X or SR-X instruments or testing directly through Quanterix's in-house Accelerator Lab, a CLIA-licensed, ISO 15189-accredited facility providing contract biomarker testing services to global partners in pharma, biotech, and academia.
Research suggests that phosphorylated tau proteins, including P-tau217 (搜索), may serve as critically important biomarkers for Alzheimer's disease (搜索) diagnosis. These biomarkers have demonstrated the ability to distinguish the condition from other forms of neurodegenerative disease and have shown potential to serve as valuable tools for identifying patients with mild cognitive impairment (搜索).
Technology Platform and Market Position
Together, the Simoa® and spatial biology platforms offer researchers a powerful combination of tissue- and fluid-based biomarker discovery to accelerate translation from bench to bedside. The combined company now offers a uniquely integrated platform that connects biology across blood and tissue, advancing precision medicine from discovery to diagnostics.
Quanterix has established itself as a global leader in ultra-sensitive biomarker detection with more than 3,400 peer-reviewed publications and has been a trusted partner to the scientific community for nearly two decades. Following the 2025 acquisition of Akoya Biosciences (搜索), the combined company now has 1,396 installed instruments worldwide.